Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study

BACKGROUND: Glioblastoma (GBM) has a poor prognosis, and patients with epidermal growth factor receptor (EGFR) amplification have an even worse prognosis. Nimotuzumab is an EGFR monoclonal antibody thought to play a significant role in the treatment of GBM. This paper presents a retrospective cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: She, Lei, Gong, Xuan, Su, Lin, Liu, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Neuro-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847561/
https://www.ncbi.nlm.nih.gov/pubmed/36181764
http://dx.doi.org/10.1093/oncolo/oyac202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847561/
https://www.ncbi.nlm.nih.gov/pubmed/36181764
http://dx.doi.org/10.1093/oncolo/oyac202

Ejemplares similares